(NasdaqGM:NNOX), Recorded noted regulatory successes with FDA general use clearance and granting of CE Mark in the EU Advanced commercialization globally, signing new customer and channel partner agreements for Nanox.ARC and Nanox AI Management to host conference call and webcast Monday, March 31, 2025 at 8:30 AM ET PETACH TIKVA, Israel, March 31, 2025 (GLOBE […]
(NASDAQ:OKYO), Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term Stability Urcosimod stable in single-use ampoules for more than 21/2 years FDA requires drug to show long-term shelf stability for approval Daily administration to patients via ampoules can minimize risk of contamination LONDON and NEW YORK, March 31, 2025 (GLOBE
(TSX-V:NOCR),(Pinksheets:NOCRF),(PinkSheets:NOCRF),(Boerse Frankfurt – Freiverkehr:03E), VANCOUVER, British Columbia, March 31, 2025 (GLOBE NEWSWIRE) — Norden Crown Metals Corporation (“Norden Crown” or the “Company“) (TSXV:NOCR, OTC:NOCRF, Frankfurt:03E) announces it has changed its name to Domestic Metals Corp. (TSXV:DMCU) in accordance with the provisions of the Business Corporations Act (British Columbia). In connection with the name change, new
(NasdaqGM:COOT), COOTAMUNDRA, Australia, March 31, 2025 (GLOBE NEWSWIRE) — Australian Oilseeds Holdings Limited, a Cayman Islands exempted company (the “Company”) (NASDAQ: COOT) today announced financial results for its second quarter fiscal 2025 ended December 31, 2024. Second Quarter Fiscal 2025 Financial Highlights Compared to Prior Year Sales revenue increased 4.5% to A$10.4 million reflecting increased
(Other OTC:LKNCY),(OTC US:LKNCY), BEIJING, March 31, 2025 (GLOBE NEWSWIRE) — Luckin Coffee Inc. (“Luckin Coffee” or the “Company”) (OTC: LKNCY) today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “2024 Annual Report”) with the U.S. Securities and Exchange Commission (the “SEC”). The 2024
(NASDAQ:BCDA), Increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE) observed study-wide, despite primary composite efficacy endpoint not reaching statistical significance Statistically significant improvement in composite outcome measure comprised of survival, MACCE, and quality of life seen in patients suffering from active heart stress (those with elevated NTproBNP and BNP biomarkers) treated with
(NASDAQ:INAB), NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced today a poster presentation on its potentially breakthrough next generation γδ T cell-based T cell engager (TCE) platform at the American Association for Cancer Research (AACR)
(NasdaqGM:BIOR), SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) — Biora Therapeutics, a biotech company developing the first swallowable autoinjector, today announced the successful completion of its court-supervised restructuring. Through the restructuring process, Biora achieved an improved balance sheet with deleveraged debt and significant new financing to support the business going forward. Biora has emerged from
NASHVILLE, Tenn., March 31, 2025 (GLOBE NEWSWIRE) — 360 Privacy, provider of the leading digital executive protection platform, today announced the appointment of three key executives to strengthen its leadership team. These strategic appointments will support the company's ambitious growth plans following its recent funding round from FTV Capital and advance its mission to provide
(NASDAQ:AMRN), DUBLIN and BRIDGEWATER, N.J., March 31, 2025 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid (EPA) on lipoprotein(a) [Lp(a)]-enriched plasma and the effects of a glucagon-like peptide-1 (GLP-1) receptor agonist in combination with EPA on the expression of proteins in endothelial